Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice

Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice

Neutrophils have been implicated in initiating and perpetuating systemic lupus erythematosus and the resultant kidney damage in lupus nephritis (LN) patients, in part through an excessive release of neutrophil serine proteases (NSPs). NSP zymogens are activated by dipeptidyl peptidase 1 (DPP1) durin...

Full description

Bibliographic Details
Main Authors: Kuan-Ju Chen, Jimin Zhang, Daniel LaSala, Jessica Basso, Donald Chun, Yuchen Zhou, Patrick P. McDonald, Walter R. Perkins, David C. Cipolla
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
brensocatib
neutrophil serine proteases (NSP)
lupus nephritis (LN)
interferon-alpha (IFNα)
systemic lupus erythematosus (SLE)
DPP1 inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185727/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185727/full

Similar Items